Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Helix BioPharma Corp. (HBPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
At close: 01:15PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2500
Open0.2500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2500 - 0.2500
52 Week Range0.2500 - 0.8800
Volume75
Avg. Volume130
Market Cap35.488M
Beta (5Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateJun 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HBPCF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HELIX BIOPHARMA CORP
    VCEL: Lowering target price to $27.00VERICEL CORP has an Investment Rating of SELL; a target price of $27.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • ACCESSWIRE

    Helix BioPharma Corp. Provides Corporate Update

    RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021.

  • ACCESSWIRE

    Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

    RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021.

  • ACCESSWIRE

    Helix BioPharma Corp. Extends Period to Exercise Warrants

    RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it is extending the exercise period of a total of 1,520,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties, for a period of two years from their current expiry dates (the "Warrant Extensio

Advertisement
Advertisement